ZARAGOZA, Spain and FRANKLIN LAKES, NJ, April 27, 2021 / PRNewswire / – CerTest Biotec today partnered with BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical device company, to announce the VIASURE SARS-CoV-2 (N1 + N2) real-time PCR detection kit for the BD MAX ™ Molecular Diagnostic System can now work with saliva samples.
This gives BD MAX ™ System users greater flexibility with three sample collection alternatives: nasopharyngeal, oropharyngeal, and saliva. This kit with CE marking according to IVD guideline (98/79 / CE) recognizes all currently identified variants of SARS-CoV-2.
As the COVID-19 pandemic continues to have an impact Europe With additional lockdowns planned in some countries, the ability to test a large portion of the population and identify infected individuals is critical to contain the spread and limit additional waves of the disease.
“Together with BD, we can now offer patients a non-invasive way to be tested for COVID-19, combining that ease and convenience with the sensitivity and specificity of the RT-PCR method,” he said Nelson Fernandes, Managing Director of CerTest BioTec.
The BD MAX ™ System, a molecular diagnostic platform, is widely used in hundreds of laboratories across the EU. Each unit can return results in two to three hours and can analyze hundreds of samples over a 24 hour period.
“This new sample type alternative for the real-time PCR detection kit VIASURE SARS-CoV-2 (N1 + N2) for the BD MAX ™ system complements our versatile breathing menu and is a step further in our goal of reaching more patients with the right goal Test and at the right time, “said Nikos Pavlidis, Vice President for Molecular Diagnostics at BD.
The VIASURE SARS-CoV-2 (N1 + N2) real-time PCR detection kit for the BD MAX ™ molecular diagnostic system is sold through BD’s distribution network. The test snaps into the test-specific position on the BD MAX ™ ExK ™ TNA extraction strip supplied by BD.
Visit to find a BD representative or request information www.bd.com or www.certest.es. VIASURE kits are not available in the United States. Product availability may vary in different countries. Please contact your local BD representative.
One of the largest global medical device companies in the world, BD is driving the world of health by improving medical discovery, diagnostics, and care delivery. The company supports the heroes at the frontline of the healthcare system by developing innovative technologies, services, and solutions that help advance both clinical therapy for patients and the clinical process for healthcare providers. BD and its 70,000 employees have a passion and dedication to improving the safety and efficiency of the clinician’s nursing process, enabling laboratory scientists to accurately identify disease, and enhancing researcher skills to develop the next generation of diagnostics and therapeutics. BD is present in virtually every country and works with organizations around the world to address some of the most challenging global health problems. By working closely with customers, BD can help improve outcomes, reduce costs, increase efficiency, improve safety, and expand access to health care. For more information on BD, see bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and twitter @ BDandCo.
CerTest Biotec is a European company founded in 2002 to develop and manufacture diagnostic in vitro medical devices. Today CerTest is a global company that consists of 5 business units and offers one of the broadest portfolios for in-vitro diagnostics of humans. The company bases its future on strong technical knowledge and expertise in the detection of human diseases. The latest generation of CerTest laboratories, state-of-the-art technical equipment and qualified specialists are the keys to providing reliable solutions for the medical diagnostician.
View original content to download multimedia:http://www.prnewswire.com/news-releases/certest-biotec-bd-announce-addition-of-saliva-to-the-ce-marked-viasure-sars-cov-2-n1n2-real-time- pcr-detection-kit-for-bd-max-molecular-diagnostic-system-301277463.html
Source BD (Becton, Dickinson and Company)